JPS5933211A - Oleaginous ointment - Google Patents
Oleaginous ointmentInfo
- Publication number
- JPS5933211A JPS5933211A JP14319782A JP14319782A JPS5933211A JP S5933211 A JPS5933211 A JP S5933211A JP 14319782 A JP14319782 A JP 14319782A JP 14319782 A JP14319782 A JP 14319782A JP S5933211 A JPS5933211 A JP S5933211A
- Authority
- JP
- Japan
- Prior art keywords
- oil
- ointment
- base
- polyoxyethylene alkyl
- polyoxyethylene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002674 ointment Substances 0.000 title claims abstract description 19
- -1 glycerol fatty acid ester Chemical class 0.000 claims abstract description 27
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims abstract description 18
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 15
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 8
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 8
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 7
- 239000000194 fatty acid Substances 0.000 claims abstract description 7
- 229930195729 fatty acid Natural products 0.000 claims abstract description 7
- 150000005215 alkyl ethers Chemical class 0.000 claims abstract description 6
- 239000004359 castor oil Substances 0.000 claims abstract description 6
- 235000019438 castor oil Nutrition 0.000 claims abstract description 6
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims abstract description 6
- 125000005907 alkyl ester group Chemical group 0.000 claims abstract description 5
- 239000003883 ointment base Substances 0.000 claims abstract description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 17
- 229910052708 sodium Inorganic materials 0.000 claims description 17
- 239000011734 sodium Substances 0.000 claims description 17
- 239000003921 oil Substances 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 9
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical group CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 8
- 235000011187 glycerol Nutrition 0.000 claims description 7
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 4
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 4
- 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 claims description 2
- LRZBIPQJHILPJI-UHFFFAOYSA-N 2,3-dihydroxypropyl 2-(2,3-dihydroxypropyl)octadecanoate Chemical compound CCCCCCCCCCCCCCCCC(CC(O)CO)C(=O)OCC(O)CO LRZBIPQJHILPJI-UHFFFAOYSA-N 0.000 claims description 2
- RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 claims description 2
- BKZCZANSHGDPSH-KTKRTIGZSA-N [3-(2,3-dihydroxypropoxy)-2-hydroxypropyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)COCC(O)CO BKZCZANSHGDPSH-KTKRTIGZSA-N 0.000 claims description 2
- RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- 239000007779 soft material Substances 0.000 claims 1
- 229960001193 diclofenac sodium Drugs 0.000 abstract description 5
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 abstract description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 abstract description 4
- 229940058015 1,3-butylene glycol Drugs 0.000 abstract description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 abstract description 2
- 238000004090 dissolution Methods 0.000 abstract 2
- 239000002260 anti-inflammatory agent Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000003637 steroidlike Effects 0.000 abstract 1
- 235000019198 oils Nutrition 0.000 description 5
- 239000013078 crystal Substances 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 3
- 239000012752 auxiliary agent Substances 0.000 description 3
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
【発明の詳細な説明】
本発明はジクロツェナフナトリウムを特定のｍ屏補助剤
により油性軟膏基剤中に浴解、配合してなる油性軟膏に
関１−るものである。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to an oily ointment prepared by dissolving diclozenaf sodium into an oily ointment base using a specific additive.
ジクロルツェナフナトリウムは非ステロイド抗炎症薬と
して良（知られているか、油性基剤中に雉浴性であるた
め、油性軟膏中に俗解して配合することか困難であった
。しかも単に軟営基剤中に混合分散させるたけではジク
ロツェナフナトリウムの経皮吸収性に乏１−＜、充分な
る薬効を期待することはできない。Dichlorzenaf sodium is known as a good non-steroidal anti-inflammatory drug, but because it has a pheasant-like property in an oily base, it has been difficult to incorporate it into an oily ointment. If only mixed and dispersed in the base, diclozenaf sodium has poor transdermal absorption, and sufficient medicinal efficacy cannot be expected.
不発明省等はかかる欠点を排除する目的で、種々の条件
下におけるジクロツェナフナトリウムの油性基剤中への
配合性を検討した結果、特定の俗解補助剤を用いること
により油性基剤中にジクロツェナフナトリウムを俗解状
態で配合することか可能であることを見出し、本発明を
完成するに至った。In order to eliminate such drawbacks, the Ministry of Invention and others investigated the incorporation of diclozenaf sodium into an oily base under various conditions and found that it can be incorporated into an oily base by using a specific auxiliary agent. The present inventors have discovered that it is possible to incorporate diclozenaf sodium in a conventional manner, and have completed the present invention.
本発明の目的とするところは効果の高いジクロツェナフ
ナトリウム配合油性軟膏を提供することにあり、その要
旨とするところはジクロツェナフナトリウム０．５〜５
％、俗解補助剤としてプロピレングリコール、１．３−
７’チレンｆ リ：ｌ−／ｌ／、ポリエチレングリコー
ル、グリセリン、グリセリン脂肪酸エステル、ポリオキ
シエチレン硬化ヒマシ油、ポリオキシエチレンアルキル
エーテル、ポリオキシエチレンアルキルエステルあるい
はそれらの混合物１〜５０％及び油性軟膏基ハリ４５〜
９８．５％からなる油性軟膏に存する。The purpose of the present invention is to provide a highly effective oil-based ointment containing diclozenaf sodium.
%, propylene glycol as a popular adjuvant, 1.3-
7'tylene f li:l-/l/, polyethylene glycol, glycerin, glycerin fatty acid ester, polyoxyethylene hydrogenated castor oil, polyoxyethylene alkyl ether, polyoxyethylene alkyl ester or a mixture thereof 1-50% and oily ointment Kihari 45~
It consists of an oily ointment consisting of 98.5%.
本発明において用いる俗解補助剤としては、プロピレン
グリコール、１．３−ブチレンクリコール、ポリエチレ
ングリコール、グリセリン、グリ七゛リン脂肪酸エステ
ル、ポリオキシエチレン硬化ヒマシ油、ポリオキシエチ
レンアルキルエーテル。Commonly used adjuvants used in the present invention include propylene glycol, 1,3-butylene glycol, polyethylene glycol, glycerin, glycerol fatty acid ester, polyoxyethylene hydrogenated castor oil, and polyoxyethylene alkyl ether.
ポリオキシエチレンアルキルニスエルあるいはそれらの
混合物である。Polyoxyethylene alkyl nysyl or a mixture thereof.
さらにかかる浴１ｊＦ（補助剤に於て、ポリエチレング
リコールとしては一般式［（ＯＣＨ２（ＣＨ２ＱＣ）１
２）ｎＣＨ２０Ｉ−１で表わされ、ｎ＝３〜２１０のも
のか好ましく用いられ、グリセリン脂肪酸エステルとし
ては、グリセリルモノステアレート、グリセリルモノオ
レエート、ジグリセリルモノステアレート、ジグリセリ
ルモノオレエートが好ましく用いられ、ポリオキシエチ
レン硬化ヒマシ油としては、エチレンオキサイド付加モ
ル数が５〜１００のものか好ましく用いられ、ポリオキ
シエチレンアルキルエーテルとしては、エチレンオキサ
イド付加モル数か１〜１００、アルキル基としてはＣＩ
２〜Ｃ２□のものが好まｔ、 ＜ 用いられ、ポリオキ
シエチレンアルキルエステルとしてはエチレンオキサイ
ド付加モル数か１０以ド、アルキル基としてはＣＩ２〜
Ｃ２□で、ＨＩ−Ｂ値１０以下のものか好ま（−＜用い
られる。Furthermore, in the bath 1jF (auxiliary agent), the polyethylene glycol has the general formula [(OCH2(CH2QC)1
2) It is represented by nCH20I-1, and those with n=3 to 210 are preferably used, and the glycerin fatty acid esters include glyceryl monostearate, glyceryl monooleate, diglyceryl monostearate, and diglyceryl monooleate. The polyoxyethylene hydrogenated castor oil preferably has an added mole of ethylene oxide of 5 to 100, and the polyoxyethylene alkyl ether preferably has an added mole of ethylene oxide of 1 to 100 and the alkyl group is CI
2~C2□ is preferable and < is used, the polyoxyethylene alkyl ester is 10 or more moles of ethylene oxide added, and the alkyl group is CI2~
C2□ and HI-B value of 10 or less is preferable (-< used.
以上の他に一般的非イオン界面活性剤も場合によっては
使用ｉｉＪ能である。In addition to the above, common nonionic surfactants may also be used in some cases.
ジクロツェナフナトリウムの含有量は０．５〜５％であ
る。含有量を５％以上にしてもジクロツェナフナトリウ
ムの薬理効果の向上は期待できず、その上非ステロイド
抗炎症薬と（−ての有用性に於て問題を生ずる割卵性が
ある。The content of diclozenaf sodium is 0.5-5%. Even if the content is increased to 5% or more, no improvement in the pharmacological effects of diclozenaf sodium can be expected, and moreover, it has a splitting property that poses a problem in its usefulness as a non-steroidal anti-inflammatory drug.
油性基剤としてはプラスティベースが最も配合団にすぐ
れていたが、他の一般的油性軟賃基剤への配合も当然の
ことながら可能である。例えばオリーブ油、ナタネ油、
スクワラン、流動〕くラフイン、パラフィンワックス、
マイクロクリスタリンワックス、ミツロウ、高級アルコ
ール類、高級脂肪酸類等である。油性基剤の選択はその
軟膏の目的に合わせて適宜性なわれるべきである。As an oil base, Plastibase was found to have the best compounding properties, but it is of course possible to blend it with other general oil bases. For example, olive oil, rapeseed oil,
Squalane, liquid rough-in, paraffin wax,
These include microcrystalline wax, beeswax, higher alcohols, and higher fatty acids. The selection of an oily base should be made appropriately depending on the purpose of the ointment.
次に本発明の油性軟↑オの製造方法について以ｆに述べ
る。Next, the method for producing the oil-based soft ↑O of the present invention will be described below.
まず、ジクロツェナフナトリウムに上述の俗解補助剤を
加え、加温してジクロツェナフナトリウムを完全に１６
１’ｌｌさせる。これにたとえばプラスティベースの如
き油性基剤をさらに加えて均一に混合（−て製造する。First, add the above-mentioned auxiliary agent to diclozenaf sodium and heat to completely remove diclozenaf sodium to 16
Let it be 1'll. To this, an oily base such as Plastibase is further added and mixed uniformly.
油性基剤としてパラフィンワックス等め固形基剤を用い
る場合は、その融点より５〜１０’高い温度に加温して
１１解１．たのち、混合して均一な液状物とし、常法に
より製造する。When using a solid base such as paraffin wax as the oily base, heat the base to a temperature 5 to 10' higher than its melting point. Thereafter, the mixture is mixed to form a uniform liquid, which is then manufactured by a conventional method.
俗解補助剤はジクロフエナクナトリウムに対１゜て通常
的２〜１０ 、＠ 、７ｆを使用する。The commonly used adjuvant is usually 2-10, 7f to diclofenac sodium.
以下実施例により本発明を史に具体的に説明するか、本
発明は実！崩例により何等限定されるものではないこと
は当然である。Hereinafter, the present invention will be explained in more detail with reference to Examples. It goes without saying that the examples are not limited in any way.
実施例１
ジクロツェナフナトリウム １％ポリエチレン
グリコール４００６％
プラスティベース ９３％十６己の処方
割合によりジクロツェナフナトリウムにポリエチレング
リコール４００を加え、約５０℃に加温して完全に混合
浴解させ、これにプラスティベームを加え、均一に混合
して目的の軟・）４を得た。Example 1 Diclzenaf sodium 1% polyethylene glycol 4006% Plastibase 93% Polyethylene glycol 400 was added to diclozenaf sodium according to a prescription ratio of 16%, and the mixture was heated to about 50°C to completely dissolve the mixture. , Plastivame was added to this and mixed uniformly to obtain the desired soft product 4).
かくしてイ４Ｊた軟面を一２０℃、５″Ｇ、室温及び４
０′Ｃに保ちつつそれぞれ１５．３０．６０及び９０日
間放置［−またのち顕做鋭下に親祭ｌ−たが、いずれの
場合にも結晶の析ＬＬｉ ＆す全くみとめられなかった
。Thus, the soft surface was heated to 20°C, 5″G, room temperature and 4°C.
The samples were left at 0'C for 15, 30, 60 and 90 days, respectively, and then under close observation, but no crystallization was observed in either case.
すなわち本発明による油性軟膏はジクロツェナフナトリ
ウムは完全に浴解し、長ＪＬＩｊ間にわたって結晶の析
出が全くなく、その効果か持続するものでルンる。That is, in the oil-based ointment according to the present invention, diclozenaf sodium is completely dissolved in the bath, and there is no precipitation of crystals over a long period of time, and the effect is sustained.
実施例２
ジクロツェナフナトリウム １％ポリオキシ
エチレンモノステアレート（Ｅ、０．２） １０％
プラスティペース ８９％上記処方割
合によりジクロツェナフナトリウムにポリオキシエチレ
ンモノステアレート（Ｅ、０．２）を加え、約７０℃に
加温して完全に混合浴解する。Example 2 Diclzenaf sodium 1% Polyoxyethylene monostearate (E, 0.2) 10%
Plastipace 89% Polyoxyethylene monostearate (E, 0.2) is added to diclozenaf sodium according to the above prescription ratio, and the mixture is heated to about 70°C to completely dissolve the mixture.
これにプラスティベースを加え、均一に混合して目的の
軟膏を得た。Plastibase was added to this and mixed uniformly to obtain the desired ointment.
かくして得た軟膏を実施例１と全く回−条汗−トにて顕
微鋭により観察し７たか、結晶析出は全くみとめられな
かった。The ointment thus obtained was observed under a microscopic microscope in the same manner as in Example 1, and no crystal precipitation was observed.
実施例３
ジクロツェナタナトリウム １％グリセリルモ
ノステアレート ８％ポリエチレンクリコール４
００ ２％プラスティベース ８
９％上記処方利合によりジクロフェナクナトリウムにグ
リセリルモノステアレー１・及びポリエチレングリコー
ル４００を加え、これを約７０°ＣＫ加搗シ、て完全に
混合＋ａ解する。これにプラスティベースを加へ、均一
に滌合しで目的とする軟Ａ゛を＃４Ｉ、実が１１例１と
全く同一条件下に顕微鋭にて観察したか。Example 3 Diclzenata sodium 1% glyceryl monostearate 8% polyethylene glycol 4
00 2% Plastibase 8
9% Glyceryl monostearate 1 and polyethylene glycol 400 were added to diclofenac sodium according to the above prescription ratio, and the mixture was thoroughly mixed and dissolved at approximately 70°C. Plastibase was added to this, mixed uniformly, and the desired soft A was #4I, which was observed under a microscopic microscope under exactly the same conditions as Example 1.
結晶の析出は全くみとめられなかった。No crystal precipitation was observed at all.
実施例４
ジクロ７エツークノートリウム ５％ポリエ
チレンクリコール４００ １５％ポリオキシエチ
レンモノステアレート（Ｅ、０．２） ＋ ５％グラ
スティベース ６５％モノステアレート
（Ｅ、０．２）を加え、これを約７ｏ０ｃに加温して完
全に混合浴解し、これにプラスティベースを加えて均一
に混合して油性駄賃を侍た。Example 4 Dicro 7 Etsuk Notorium 5% Polyethylene Glycol 400 15% Polyoxyethylene Monostearate (E, 0.2) + 5% Glasty Base 65% Monostearate (E, 0.2) was added, This was heated to about 7o0C to completely dissolve the mixing bath, and Plastibase was added thereto and mixed uniformly to remove the oily residue.
か＜ １．てイｎた軟膏を実施例１と全（同一条件下に
て諺ｌ敬疑によつｊｌｌ祭した結果、室温及び４０’Ｃ
にて９０日間放置した場合にはやや結晶析出とみなされ
るものがみとめられた。Or < 1. The ointment was applied under the same conditions as in Example 1.
When the sample was left for 90 days, a slight amount of crystal precipitation was observed.
特許出願人 佐藤製薬株式会社Patent applicant: Sato Pharmaceutical Co., Ltd.
Claims (7)
由助４リドしてプロピレングリコールレンゲリコール、
ポリエチレンクリコール、クリセリン、グリセリン脂肪
酸エステル、ポリオキシエチレン硬化ヒマシ油，ポリオ
キシエチレンアルキルエーテル、ポリオキシエチレンア
ルキルエステルあるいはそれらの混合物１〜５０％及び
油性軟・Ｘ：基剤４５〜９８．５％からなることを特徴
とする油性軟膏。(1) Diclozenaf sodium 0.5-5%, Yinkair
Yusuke 4 lido propylene glycol lengelicol,
Polyethylene glycol, chrycerin, glycerin fatty acid ester, polyoxyethylene hydrogenated castor oil, polyoxyethylene alkyl ether, polyoxyethylene alkyl ester, or a mixture thereof 1-50% and oil-based soft X: base 45-98.5% An oily ointment characterized by comprising:
０Ｔｌで表わされるポリエチレングリコールのｎが３〜
２１０であることを特徴とする特許請求の範囲ｆｉｌ記
載の油性軟膏。(2) General formula HOCH2(CH20CH2)nCH2
n of polyethylene glycol represented by 0Tl is 3 to
210. The oil-based ointment according to claim fil.
アレート、グリセリルモノオレエート、ジグリセリルモ
ノステアレート、ジグリセリルモノオレエートであるこ
とを特徴とする特許請求の範囲（１）記載の油性軟膏。(3) The oil-based ointment according to claim (1), wherein the glycerin fatty acid ester is glyceryl monostearate, glyceryl monooleate, diglyceryl monostearate, or diglyceryl monooleate.
サイド付加モル数５〜＋００であることを特徴とする特
許請求の範囲１０記載の油性軟膏。(4) The oily ointment according to claim 10, characterized in that it is polyoxyethylene hydrogenated castor oil or has an added mole of ethylene oxide of 5 to +00.
７’−ｖ−イド付加モル数１〜１００であり且つアルキ
ル基の炭素数１２〜２２であることを特徴とする特許請
求の範囲（１）記載の油性軟膏。(5) The oil base according to claim (1), wherein the polyoxyethylene alkyl ether has an added mole of ethylene 7'-v-ide of 1 to 100 and an alkyl group having 12 to 22 carbon atoms. ointment.
オキサイド付加モル数１０以下であり且つアルキル基の
炭素数１２〜２２であることを特徴とする特許請求の範
囲１１）記載の油性軟質。(6) The oil-based soft material according to claim 11), wherein the polyoxyethylene alkyl ester has an added mole of ethylene oxide of 10 or less, and the alkyl group has 12 to 22 carbon atoms.
徴とする特許請求の範囲（１）記載の油性軟質。(7) The oil-based ointment base according to claim (1), wherein the oil-based ointment base is Plastipace.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP14319782A JPS5933211A (en) | 1982-08-20 | 1982-08-20 | Oleaginous ointment |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP14319782A JPS5933211A (en) | 1982-08-20 | 1982-08-20 | Oleaginous ointment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS5933211A true JPS5933211A (en) | 1984-02-23 |
Family
ID=15333125
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP14319782A Pending JPS5933211A (en) | 1982-08-20 | 1982-08-20 | Oleaginous ointment |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5933211A (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0165696A2 (en) * | 1984-05-10 | 1985-12-27 | American Home Products Corporation | Improved transdermal dosage form |
| JPS6185328A (en) * | 1984-10-02 | 1986-04-30 | Kao Corp | Percutaneous absorption promoter and external preparation for skin containing same |
| JPS6191817A (en) * | 1984-10-08 | 1986-05-09 | 日本電気株式会社 | Electromagnetic relay |
| US4711906A (en) * | 1984-12-21 | 1987-12-08 | Merckle Gmbh | Liquid diclofenac preparations |
| JPH03109321A (en) * | 1989-09-22 | 1991-05-09 | Ss Pharmaceut Co Ltd | Drug composition for external use |
| WO1991012821A1 (en) * | 1990-03-02 | 1991-09-05 | Shiseido Company, Ltd. | Oil-in-water emulsion composition containing nonsteroidal antiphlogistic analgesic |
| JPH05273218A (en) * | 1992-03-25 | 1993-10-22 | Aloka Co Ltd | Dispensation |
| US6262121B1 (en) | 1997-07-18 | 2001-07-17 | Teikoku Seiyaku Co., Ltd. | Oily patches for external use containing diclofenac sodium |
| JPWO2002098396A1 (en) * | 2001-05-31 | 2004-09-16 | 久光製薬株式会社 | Transdermal patch |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5735509A (en) * | 1980-08-12 | 1982-02-26 | Grelan Pharmaceut Co Ltd | Analgesic and antiphlogistic cream |
| JPS5770824A (en) * | 1980-10-20 | 1982-05-01 | Nippon Saafuakutanto Kogyo Kk | Vehicle for medicine |
-
1982
- 1982-08-20 JP JP14319782A patent/JPS5933211A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5735509A (en) * | 1980-08-12 | 1982-02-26 | Grelan Pharmaceut Co Ltd | Analgesic and antiphlogistic cream |
| JPS5770824A (en) * | 1980-10-20 | 1982-05-01 | Nippon Saafuakutanto Kogyo Kk | Vehicle for medicine |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0165696A3 (en) * | 1984-05-10 | 1987-05-20 | American Home Products Corporation | Improved transdermal dosage form |
| EP0165696A2 (en) * | 1984-05-10 | 1985-12-27 | American Home Products Corporation | Improved transdermal dosage form |
| JPH0764754B2 (en) * | 1984-10-02 | 1995-07-12 | 花王株式会社 | Transdermal absorption enhancer and external preparation for skin containing the same |
| JPS6185328A (en) * | 1984-10-02 | 1986-04-30 | Kao Corp | Percutaneous absorption promoter and external preparation for skin containing same |
| JPS6191817A (en) * | 1984-10-08 | 1986-05-09 | 日本電気株式会社 | Electromagnetic relay |
| JPH0441451B2 (en) * | 1984-10-08 | 1992-07-08 | Nippon Electric Co | |
| US4711906A (en) * | 1984-12-21 | 1987-12-08 | Merckle Gmbh | Liquid diclofenac preparations |
| JPH03109321A (en) * | 1989-09-22 | 1991-05-09 | Ss Pharmaceut Co Ltd | Drug composition for external use |
| JPH07121860B2 (en) * | 1989-09-22 | 1995-12-25 | エスエス製薬株式会社 | Topical drug composition |
| WO1991012821A1 (en) * | 1990-03-02 | 1991-09-05 | Shiseido Company, Ltd. | Oil-in-water emulsion composition containing nonsteroidal antiphlogistic analgesic |
| US5256691A (en) * | 1990-03-02 | 1993-10-26 | Shiseido Company Ltd. | Oil-in-water type emulsified composition comprising non-steroidal antiphlogistic and analgesic drug |
| JPH05273218A (en) * | 1992-03-25 | 1993-10-22 | Aloka Co Ltd | Dispensation |
| US6262121B1 (en) | 1997-07-18 | 2001-07-17 | Teikoku Seiyaku Co., Ltd. | Oily patches for external use containing diclofenac sodium |
| JPWO2002098396A1 (en) * | 2001-05-31 | 2004-09-16 | 久光製薬株式会社 | Transdermal patch |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5061700A (en) | Glyceryl acetate ointment vehicles | |
| US5104656A (en) | Percutaneous treatment with a high potency non-steroidal anti-inflammatory agent | |
| TW200409646A (en) | Topical composition | |
| JPS5815909A (en) | Antimycotic agent for external use | |
| US2241331A (en) | Suppository | |
| JPS5933211A (en) | Oleaginous ointment | |
| GB2135576A (en) | Hydrocortisone butyrate propionate creams | |
| JPH0729929B2 (en) | Cream containing hydrocortisone diester | |
| JPH0134968B2 (en) | ||
| KR19990044454A (en) | Compositions for Sustained Rectal Administration | |
| US2948686A (en) | Thixotropic and fast breaking skin cleaner emulsion and process for producing the same | |
| US3594473A (en) | Anti-haemorrhoidally active preparations and the use of a d-glucofuranoside in such preparations | |
| ES2305393T3 (en) | WATER-BASED EMULSIONING-WAX GELS. | |
| JPH04100535A (en) | Oil in polyhydric alcohol type emulsified composition | |
| JPS59137408A (en) | ointment | |
| JPH0140806B2 (en) | ||
| JP3031990B2 (en) | Anti-inflammatory analgesic cream composition | |
| JP3509118B2 (en) | Method for improving consistency of cosmetics or external preparation for skin | |
| JPH0135807B2 (en) | ||
| JP3803595B2 (en) | Urea-containing external composition for skin | |
| JP2653089B2 (en) | Liquid skin cleanser composition | |
| KR100560892B1 (en) | Stable Aspirin Ointment | |
| JPS5923292B2 (en) | γ-oryzanol preparation | |
| JPS6029758B2 (en) | Jelly-like cleaning composition | |
| JPH10101555A (en) | Gel cream agent |